ADMA Biologics reported second quarter 2026 financial results with total revenue of $124.4 million and GAAP net income of $37.8 million, both increasing year-over-year. ASCENIV revenue grew 24% to $102.9 million, while BIVIGAM revenue declined 49% to $19.4 million but showed sequential stabilization. The company reiterated its full-year 2026 guidance, projecting total revenue between $530 million and $560 million, adjusted net income of $170 million to $200 million, and adjusted EBITDA of $265 million to $300 million. During the quarter, ADMA repurchased approximately 7.1 million shares under its existing program, bringing year-to-date buybacks to 13.8 million shares. The firm also advanced preclinical activities for its pipeline candidate SG-001 and submitted real-world data on ASCENIV to the ACAAI Annual Scientific Meeting. ADMA Biologics is a U.S.-based biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics.